These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 29381964)
1. Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date. Chen C; Yin S; Zhang S; Wang M; Hu Y; Zhou P; Jiang S Medicine (Baltimore); 2017 Nov; 96(47):e8733. PubMed ID: 29381964 [TBL] [Abstract][Full Text] [Related]
2. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056 [TBL] [Abstract][Full Text] [Related]
3. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894 [TBL] [Abstract][Full Text] [Related]
4. How effective is temozolomide for treating pituitary tumours and when should it be used? Halevy C; Whitelaw BC Pituitary; 2017 Apr; 20(2):261-266. PubMed ID: 27581836 [TBL] [Abstract][Full Text] [Related]
7. Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide. Felker J; Patterson B; Wrubel D; Janss A J Pediatr Endocrinol Metab; 2016 Dec; 29(12):1413-1415. PubMed ID: 27815961 [TBL] [Abstract][Full Text] [Related]
8. Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission. Barkhoudarian G; Palejwala SK; Ogunbameru R; Wei H; Eisenberg A; Kelly DF World Neurosurg; 2018 Oct; 118():118-124. PubMed ID: 30031177 [TBL] [Abstract][Full Text] [Related]
9. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Kovacs K; Horvath E; Syro LV; Uribe H; Penagos LC; Ortiz LD; Fadul CE Hum Pathol; 2007 Jan; 38(1):185-9. PubMed ID: 17056093 [TBL] [Abstract][Full Text] [Related]
10. Treatment of pituitary neoplasms with temozolomide: a review. Syro LV; Ortiz LD; Scheithauer BW; Lloyd R; Lau Q; Gonzalez R; Uribe H; Cusimano M; Kovacs K; Horvath E Cancer; 2011 Feb; 117(3):454-62. PubMed ID: 20845485 [TBL] [Abstract][Full Text] [Related]
11. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Hagen C; Schroeder HD; Hansen S; Hagen C; Andersen M Eur J Endocrinol; 2009 Oct; 161(4):631-7. PubMed ID: 19654234 [TBL] [Abstract][Full Text] [Related]
12. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature. Annamalai AK; Dean AF; Kandasamy N; Kovacs K; Burton H; Halsall DJ; Shaw AS; Antoun NM; Cheow HK; Kirollos RW; Pickard JD; Simpson HL; Jefferies SJ; Burnet NG; Gurnell M Pituitary; 2012 Sep; 15(3):276-87. PubMed ID: 22076588 [TBL] [Abstract][Full Text] [Related]
13. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Losa M; Mazza E; Terreni MR; McCormack A; Gill AJ; Motta M; Cangi MG; Talarico A; Mortini P; Reni M Eur J Endocrinol; 2010 Dec; 163(6):843-51. PubMed ID: 20870708 [TBL] [Abstract][Full Text] [Related]
14. Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review. Almalki MH; Aljoaib NN; Alotaibi MJ; Aldabas BS; Wahedi TS; Ahmad MM; Alshahrani F Hormones (Athens); 2017 Apr; 16(2):139-149. PubMed ID: 28742502 [TBL] [Abstract][Full Text] [Related]
15. The role of temozolomide in the treatment of aggressive pituitary tumors. Liu JK; Patel J; Eloy JA J Clin Neurosci; 2015 Jun; 22(6):923-9. PubMed ID: 25772801 [TBL] [Abstract][Full Text] [Related]
16. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma? Phillips J; East HE; French SE; Melcescu E; Hamilton RD; Nicholas WC; Fratkin JF; Parent AD; Luzardo G; Koch CA Hormones (Athens); 2012; 11(4):477-82. PubMed ID: 23422771 [TBL] [Abstract][Full Text] [Related]
17. Successful treatment of leptomeningeally metastasised pituitary carcinoma with temozolomide. van der Vlist A; Snijders TJ; Stades AME; Spliet WGM; De Vos FYFL Neth J Med; 2017 Dec; 75(10):451-454. PubMed ID: 29256415 [TBL] [Abstract][Full Text] [Related]
18. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. McCormack AI; Wass JA; Grossman AB Eur J Clin Invest; 2011 Oct; 41(10):1133-48. PubMed ID: 21496012 [TBL] [Abstract][Full Text] [Related]
19. Temozolomide in the management of dopamine agonist-resistant prolactinomas. Whitelaw BC; Dworakowska D; Thomas NW; Barazi S; Riordan-Eva P; King AP; Hampton T; Landau DB; Lipscomb D; Buchanan CR; Gilbert JA; Aylwin SJ Clin Endocrinol (Oxf); 2012 Jun; 76(6):877-86. PubMed ID: 22372583 [TBL] [Abstract][Full Text] [Related]
20. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Neff LM; Weil M; Cole A; Hedges TR; Shucart W; Lawrence D; Zhu JJ; Tischler AS; Lechan RM Pituitary; 2007; 10(1):81-6. PubMed ID: 17285366 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]